<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166324">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01678898</url>
  </required_header>
  <id_info>
    <org_study_id>PB-102-F01</org_study_id>
    <nct_id>NCT01678898</nct_id>
  </id_info>
  <brief_title>Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients</brief_title>
  <official_title>A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protalix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protalix</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first human treatment with PRX-102, an enzyme being developed as a long-term
      enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (alpha
      galactosidase deficiency). The safety, tolerability, and exploratory efficacy will be
      evaluated in this study of increasing doses.  Patients will be treated with infusions every
      two weeks for 12 weeks (7 infusions).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Reportings of adverse events reported by the patient and from monitoring with clinical laboratory, physical examination and ECG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gb3 concentrations</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gb3 concentrations in plasma and urine sediment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of glomerular filtration and proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Short term brief pain inventory</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>0.2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-102 0.2 mg/kg every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-102 1 mg/kg every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-102 2 mg/kg every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRX-102</intervention_name>
    <arm_group_label>0.2 mg/kg</arm_group_label>
    <arm_group_label>1 mg/kg</arm_group_label>
    <arm_group_label>2 mg/kg</arm_group_label>
    <other_name>plant cell expressed recombinant human alpha-galactosidase-A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic adult Fabry patients (≥18 yrs)

          -  Males: plasma and/or leucocyte alpha galactosidase activity (by activity assay) less
             than lower limit of normal (LLN in plasma=3.2 nmol/hr/ml, LLN in leucocytes=32
             nmol/hr/mg/protein)

          -  Females: historical genetic test results consistent with Fabry mutations

          -  Globotriaosylceramide (Gb3) concentration in urine &gt; 1.5 times upper normal limit

          -  Patients who have never received enzyme replacement therapy (ERT) in the past, or
             patients who have not received ERT in the past 6 months and have a negative anti
             alpha galactosidase antibody test

          -  Chronic kidney disease - stages 1 or 2 (CKD1 or 2) (Appendix 7) with proteinuria &gt;
             200 mg/g protein-to-creatinine ratio or equivalent, measured in a Spot urine sample,
             demonstrated in at least one of 2 separate samples (1 sample at screening visit and
             the other from historical data)

          -  The patient signs informed consent

          -  Female patients and male patients whose co-partners are of child-bearing potential
             agree to use a medically acceptable method of contraception, not including the rhythm
             method

        Exclusion Criteria:

          -  Participation in any trial of an investigational drug within 30  days prior to study
             screening

          -  Chronic kidney disease stages 3-5 (CKD 3-5) (Appendix 7)

          -  History of dialysis or renal transplantation

          -  Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB)
             therapy initiated or dose changed in the 4 weeks prior to screening

          -  Severe myocardial fibrosis by MRI (≥2 late-enhancement [LE] positive left ventricular
             segments) (Weidemann et al. 2009)

          -  History of clinical stroke

          -  Pregnant or nursing

          -  Presence of HIV and/or HBsAg and/or Hepatitis C infections

          -  Known allergies to ERT

          -  Known allergy to Gadolinium based contrast agents

          -  Presence of any medical, emotional, behavioral or psychological condition that, in
             the judgment of the Investigator and/or Medical Director, would interfere with the
             patient's compliance with the requirements of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Einat Almon, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Protalix</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Human Genetics, Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Jacob Laney</last_name>
      <phone>404-778-8518</phone>
      <email>dawn.laney@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Jeannie Visootsak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheri Copeland</last_name>
      <phone>913-588-7691</phone>
      <email>scopeland2@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Ahmad Mahdi Tuffaha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen L Pusateri</last_name>
      <phone>443-287-7124</phone>
      <email>kpusate1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Gustavo HB Maegawa, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Canfield, RN MSN</last_name>
      <phone>919-668-2195</phone>
      <email>michelle.canfield@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Marie McDonald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Baylor Institute of Metabolic Disease</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caren Swift</last_name>
      <phone>214-820-4857</phone>
      <email>Caren.Swift@baylorhealth.edu</email>
    </contact>
    <investigator>
      <last_name>Raphael Schiffmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>O &amp; O Alpan LLC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tabitha Taber</last_name>
      <phone>571-308-1906</phone>
      <email>ttaber@oandoalpan.com</email>
    </contact>
    <investigator>
      <last_name>Ozlem Goker Alpan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Victoria</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna North</last_name>
      <phone>613 9342 4219</phone>
      <email>donna.north@mh.org.au</email>
    </contact>
    <investigator>
      <last_name>Kathy Nicholls, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology and Clinical Research Private Institute</name>
      <address>
        <city>Asuncion</city>
        <country>Paraguay</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derlis Emilio Gonzalez Rodriguez, MD</last_name>
      <phone>595-21-423603</phone>
      <email>gderlis@conexion.com.py</email>
    </contact>
    <investigator>
      <last_name>Derlis Emilio Gonzales Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derralynn Hughes, MD</last_name>
      <phone>44 207 472 6588</phone>
      <email>rmgvdah@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Derralynn Hughes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Paraguay</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 4, 2014</lastchanged_date>
  <firstreceived_date>August 31, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fabry disease</keyword>
  <keyword>Alpha galactosidase deficiency</keyword>
  <keyword>Metabolic storage disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
